Remdesivir-Criteria-Save-on-Costs-Without-Affecting-Outcomes

Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyA systemwide shift to more restrictive remdesivir (Veklury, Gilead Sciences) eligibility criteria led to a substantial reduction in drug use and associated costs—without worsening clinical outcomes—according to a retrospective analysis presented at the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.figure img { width:100% !important; } figcaption { padding: 5px; backgroun